Evidence map›Paper›PMID 38751496›Full record

ArticleOcular oncology and pathology2024

Retinal Pigment Epithelial Adenoma: Initial Treatment Outcomes following Episcleral Brachytherapy.

Alaa E Fayed, Islam Y Swaify, Ayman M Khattab, Tamer A Macky, Dina H Hassanein, Shaymaa H Salah, Abdussalam M Abdullatif, Alia M Noureldine, Mariam R Fadel, Youssef A H Helmy and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ocular oncology and pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alaa E FayedDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Islam Y SwaifyDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Ayman M KhattabDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Tamer A MackyDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Dina H HassaneinDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Shaymaa H SalahDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Abdussalam M AbdullatifDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Alia M NoureldineDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Mariam R FadelDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Youssef A H HelmyDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Ayman G ElnahryDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Yasmine A MeqdadDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Yagmur S YesiltasDepartment of Ophthalmic Oncology, Cole Eye Institute, Cleveland, OH, USA.
Arun D SinghDepartment of Ophthalmic Oncology, Cole Eye Institute, Cleveland, OH, USA.
Hany HamzaDepartment of Ophthalmology, Cairo University Ocular Oncology Service, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: We aim to explore the safety and efficacy of episcleral brachytherapy as a primary management option for eyes with retinal pigment epithelial (RPE) adenoma. Methods: Retrospective chart review of the demographic, clinical, ancillary, and postoperative outcome data of patients with RPE adenoma in 2 tertiary referral centers. Tumor regression, final visual acuity, and complications were assessed. Results: Five patients (3 females and 2 males) were included. Four of the 5 eyes had peripheral and mid-peripheral lesions, while one tumor was juxtapapillary. Three eyes were treated with ruthenium-106 (100 Gray), and 2 received iodine-125 episcleral plaques (85 Gray). All eyes showed clinical and imaging-based evidence of regression. Four eyes had stable or improved visual acuity, while 1 eye exhibited one line loss of visual acuity due to radiation retinopathy. Local recurrence was not observed in any eye over a median follow-up of 24 (range 6-112) months. Conclusions: Episcleral brachytherapy is an effective management option for select cases of RPE adenoma that is capable of achieving tumor regression while maintaining favorable visual acuity. The initial safety profile of brachytherapy is good without significant vision-compromising complications.

Indexed as

AdenomaBrachytherapyEpiscleraRadiotherapyRetinal pigment epithelium

Identifiers

PMID38751496
PMCPMC11095603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.